Aberrant expression and kinase activity of Src have been found in many different tumors, including GC.4, 5 Previous studies have shown that phosphorylated mammalian target of rapamycin (p-mTOR) was significantly overexpressed in advanced GC patients' tumors and suggested that the PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mTOR) pathway is activated in GC with potential prognostic and predictive significance.6, 7 Aurora A overexpression has recently been reported in GC, and it was suggested to be associated with cancer progression and poor prognosis.8, 9, 10. This evidence concerns the gene AKT1 and gastric cancer.